Robust Call Option Trading Highlights Investor Optimism
On 14 Jul 2026, Divis Laboratories witnessed exceptional activity in its call options expiring on 28 Jul 2026. The strike price of ₹7,000 attracted the highest volume, with 22,005 contracts traded, generating a turnover of ₹3,165.42 lakhs. Open interest stood at 5,601 contracts, indicating substantial ongoing positions and a strong commitment from market participants to this bullish bet.
The underlying stock price at the time was ₹7,050.50, slightly above the strike price, suggesting that traders are positioning for further upside in the coming fortnight. This level of call option activity is notable given the stock’s recent price momentum and the broader sector environment.
Price Performance and Technical Strength
Divis Laboratories has been on a steady upward trajectory, outperforming its Pharmaceuticals & Biotechnology sector by 0.92% on the day of reporting. The stock recorded a 1-day return of 1.66%, comfortably surpassing the sector’s 0.63% gain and the Sensex’s decline of 0.50%. Over the last four consecutive trading sessions, the stock has delivered a cumulative return of 4.06%, underscoring sustained buying interest.
Technically, the stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong bullish trend. This technical strength likely underpins the elevated call option volumes, as traders anticipate continued price appreciation.
Investor Participation and Liquidity Considerations
Despite the positive price action, delivery volumes have seen a decline. On 13 Jul 2026, delivery volume was recorded at 1.61 lakh shares, down 33.73% compared to the 5-day average delivery volume. This suggests that while short-term speculative interest via options is high, longer-term investor participation through stock delivery has moderated.
Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting trade sizes up to ₹5.09 crore based on 2% of the 5-day average traded value. This liquidity profile facilitates active options trading without excessive market impact.
Mojo Score and Rating Update
Divis Laboratories currently holds a mojo score of 64.0, categorised as a 'Hold' rating. This represents a downgrade from a previous 'Buy' rating issued on 29 Jun 2026. The downgrade reflects a more cautious outlook amid valuation concerns and sector headwinds, despite the stock’s recent price strength and option market enthusiasm.
As a large-cap pharmaceutical company with a market capitalisation of ₹1,84,660 crore, Divis Laboratories remains a key player in the sector. Its mojo grade adjustment signals investors should balance the bullish technical signals with fundamental considerations.
Expiry Patterns and Strike Price Concentration
The concentration of call option activity at the ₹7,000 strike price for the 28 Jul 2026 expiry is particularly telling. This strike is near the current market price, indicating that traders expect the stock to maintain or exceed this level within the next two weeks. The high open interest at this strike suggests that many investors are either hedging existing positions or speculating on a breakout.
Such expiry patterns often precede significant price moves, as option writers and buyers adjust their positions. The expiry date being just two weeks away adds a time-sensitive element to the bullish positioning.
Sector Context and Comparative Performance
Within the Pharmaceuticals & Biotechnology sector, Divis Laboratories’ outperformance is notable. The sector has been experiencing mixed sentiment due to regulatory scrutiny and pricing pressures, yet Divis has managed to sustain momentum. Its ability to outperform the sector by nearly 1% on the day and maintain gains over multiple sessions highlights its relative strength.
Investors looking for exposure to pharmaceutical innovation and stable earnings growth may find Divis Laboratories’ current option market activity a useful barometer of market expectations.
Implications for Investors
The surge in call option volumes at near-the-money strikes, combined with the stock’s technical strength and recent price highs, suggests a predominantly bullish outlook among traders. However, the downgrade in mojo rating and falling delivery volumes caution investors to consider fundamental risks alongside technical signals.
For those seeking to capitalise on momentum, the active options market provides opportunities for leveraged exposure, but the approaching expiry date requires careful timing. Long-term investors may prefer to monitor upcoming earnings and sector developments before increasing exposure.
Conclusion
Divis Laboratories Ltd’s recent surge in call option activity underscores a strong bullish sentiment in the near term, supported by solid price performance and technical indicators. While the mojo rating downgrade introduces a note of caution, the stock’s leadership within the pharmaceutical sector and robust liquidity profile make it a focal point for traders and investors alike as expiry approaches.
